Responses to pandemic AS03-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals by Kelly, Deborah et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Responses to pandemic AS03-adjuvanted A/California/07/09 H1N1 influenza
vaccine in human immunodeficiency virus-infected individuals
BMC Immunology 2012, 13:49 doi:10.1186/1471-2172-13-49
Deborah Kelly (dvkelly@mun.ca)
Kimberley Burt (Kimberley.Burt@easternhealth.ca)
Bayan Missaghi (bayan.missaghi@easternhealth.ca)
Lisa Barrett (lisa.barrett@nih.gov)
Yoav Keynan (keynany@yahoo.com)
Keith R Fowke (fowkekr@cc.umanitoba.ca)
Michael D Grant (mgrant@mun.ca)
ISSN 1471-2172
Article type Research article
Submission date 23 March 2012
Acceptance date 27 August 2012
Publication date 31 August 2012
Article URL http://www.biomedcentral.com/1471-2172/13/49
Like all articles in BMC journals, this peer-reviewed article can be downloaded, printed and
distributed freely for any purposes (see copyright notice below).
Articles in BMC journals are listed in PubMed and archived at PubMed Central.
For information about publishing your research in BMC journals or any BioMed Central journal, go to
http://www.biomedcentral.com/info/authors/
BMC Immunology
© 2012 Kelly et al. ; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Responses to pandemic AS03-adjuvanted 
A/California/07/09 H1N1 influenza vaccine in 
human immunodeficiency virus-infected individuals 
Deborah Kelly1,2 
Email: dvkelly@mun.ca 
Kimberley Burt2 
Email: Kimberley.Burt@easternhealth.ca 
Bayan Missaghi2,3 
Email: bayan.missaghi@easternhealth.ca 
Lisa Barrett4 
Email: lisa.barrett@nih.gov 
Yoav Keynan5,6 
Email: keynany@yahoo.com 
Keith Fowke5,6 
Email: fowkekr@cc.umanitoba.ca 
Michael Grant7,8,* 
Email: mgrant@mun.ca 
1 School of Pharmacy, Memorial University of Newfoundland and Labrador, NL, 
St. John’s, Canada 
2 Eastern Health Corporation of Newfoundland and Labrador, St. John’s, Canada 
3 Division of Infectious Diseases, Memorial University of Newfoundland and 
Labrador, NL, St. John’s, Canada 
4 National Institutes of Health Institute of Allergy and Infectious Diseases, 
Bethesda, MD, USA 
5 Departments of Medical Microbiology and Community Health Sciences, 
University of Manitoba, Winnipeg, MB, Canada 
6 Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya 
7 Division of BioMedical Sciences, Faculty of Medicine, Memorial University of 
Newfoundland and Labrador, St. John’s, NL, Canada 
8 H1803- Immunology, Faculty of Medicine, Memorial University of 
Newfoundland, 300 Prince Philip Drive, St. John’s, NL A1B 3V6, Canada 
* Corresponding author. H1803- Immunology, Faculty of Medicine, Memorial 
University of Newfoundland, 300 Prince Philip Drive, St. John’s, NL A1B 3V6, 
Canada 
Abstract 
Background 
Influenza infection may be more serious in human immunodeficiency virus (HIV)-infected 
individuals, therefore, vaccination against seasonal and pandemic strains is highly advised. 
Seasonal influenza vaccines have had no significant negative effects in well controlled HIV 
infection, but the impact of adjuvanted pandemic A/California/07/2009 H1N1 influenza 
hemaglutinin (HA) vaccine, which was used for the first time in the Canadian population as 
an authorized vaccine in autumn 2009, has not been extensively studied. 
Objective 
Assess vaccine-related effects on CD4+ T cell counts and humoral responses to the vaccine in 
individuals attending the Newfoundland and Labrador Provincial HIV clinic. 
Methods 
A single dose of ArepanrixTM split vaccine including 3.75 μg A/California/07/2009 H1N1 
HA antigen and ASO3 adjuvant was administered to 81 HIV-infected individuals by 
intramuscular injection. Plasma samples from shortly before, and 1–5 months after 
vaccination were collected from 80/81 individuals to assess humoral anti-H1N1 HA 
responses using a sensitive microbead-based array assay. Data on CD4+ T cell counts, plasma 
viral load, antiretroviral therapy and patient age were collected from clinical records of 81 
individuals. 
Results 
Overall, 36/80 responded to vaccination either by seroconversion to H1N1 HA or with a clear 
increase in anti-H1N1 HA antibody levels. Approximately 1/3 (28/80) had pre-existing anti-
H1N1 HA antibodies and were more likely to respond to vaccination (22/28). Responders had 
higher baseline CD4+ T cell counts and responders without pre-existing antibodies against 
H1N1 HA were younger than either non-responders or responders with pre-existing 
antibodies. Compared to changes in their CD4+ T cell counts observed over a similar time 
period one year later, vaccine recipients displayed a minor, transient fall in CD4+ T cell 
numbers, which was greater amongst responders. 
Conclusions 
We observed low response rates to the 2009 pandemic influenza vaccine among HIV-infected 
individuals without pre-existing antibodies against H1N1 HA and a minor transient fall in 
CD4+ T cell numbers, which was accentuated in responders. A single injection of the 
ArepanrixTM pandemic A/California/07/2009 H1N1 HA split vaccine may be insufficient to 
induce protective immunity in HIV-infected individuals without pre-existing anti-H1N1 HA 
responses. 
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Background 
In autumn 2009, the A/California/07/2009 H1N1 pandemic influenza vaccine was 
recommended as a priority to essential workers and high risk individuals, including 
individuals infected with human immunodeficiency virus (HIV) [1]. While previous studies 
of influenza vaccination in HIV-infected individuals showed no significant negative effects in 
the setting of effective highly active antiretroviral therapy (HAART) [2], the 2009 H1N1 
influenza A vaccination campaign was the first to use the ASO3 adjuvant in the Canadian 
population [1]. The superiority of this oil in water adjuvant formulation of an influenza 
vaccine over non-adjuvanted formulations in enhancing vaccine antigen immunogenicity 
reduces the amount of H1N1 hemaglutinin (HA) antigen required per vaccine dose [3]. 
Therefore, it was recommended for use by Health Canada in order to optimize vaccine 
efficacy and distribution in the Canadian population [4]. Immunogenicity of vaccine antigens 
is enhanced by inflammation [5-7] and clinical trial data indicates an increased incidence of 
non-severe vaccine-associated adverse events following administration of the ASO3 
adjuvanted A/California/07/2009 H1N1 vaccine (ArepanrixTM) compared to non-adjuvanted 
influenza antigen formulations [1,3,7]. These reported events were mainly symptoms of 
localized and systemic inflammation. Frequency and severity of adverse events reported was 
similar for HIV-infected and uninfected individuals [8,9]. Acute systemic inflammation with 
leukocytosis and impaired endothelial cell function was observed in a group of HIV-infected 
individuals monitored after receiving a similar A/California/07/2009 H1N1 vaccine 
formulation [10]. Thus, there is a high likelihood that this pandemic vaccine formulation 
induced stronger and/or more sustained inflammatory responses in the recipient population 
than those induced by previous seasonal influenza vaccine formulations. To obtain more 
information on factors affecting immunogenicity of ArepanrixTM in the HIV-infected 
population, we performed a retrospective analysis of the vaccine responses of 80/81 
vaccinated individuals attending the provincial HIV clinic in Newfoundland and Labrador, 
Canada. We used a sensitive microbead-based array assay to measure humoral responses and 
investigated baseline factors associated with vaccine immunogenicity. In addition, since 
inflammation and immune activation are risk factors for HIV disease progression, even in the 
setting of HAART [11,12], we assessed whether primary vaccination with ArepanrixTM had 
any adverse effect on CD4+ T cell numbers in this group of 81 vaccinated individuals. 
Results 
Changes in CD4+ T lymphocyte counts in vaccine recipients 
General characteristics of 93 HIV-infected individuals, of whom 81 received and 12 declined 
the 2009 H1N1 vaccine, are shown in table 1. Of the vaccinated individuals, 63% (51/81) had 
plasma HIV viral loads below detectable levels (<1.6 log10), as did 67% (8/12) of the 
unvaccinated group. Twelve vaccinated individuals were not receiving antiretroviral therapy 
at the time of vaccination and through the follow-up period. For the 81 vaccine recipients, the 
mean peripheral blood CD4+ T cell count ± SD pre-vaccination was 534 ± 277/μL and post-
vaccination was 500 ± 266/μL. Excluding those vaccinated individuals whose viral load 
changed by > 1 log10 over the observation period (12/81), the mean peripheral blood CD4
+ T 
cell count ± SD pre-vaccination was 576 ± 268/μL pre-vaccination and 532 ± 261/μL post-
vaccination. Neither change was statistically significant (p = 0.16 and p = 0.11, Mann–
Whitney test for the entire group or with exclusion of those whose viral load changed by > 1 
log10 over the observation period respectively). Over a similar time period, the mean CD4
+ T 
cell count of the 12 unvaccinated HIV-infected individuals (none of whom had a change in 
HIV plasma viral load of > 1 log10 over the observation period) was 429 ± 235/μL initially and 
418 ± 180/μL at the end of the observation period. There was no significant difference in the 
median change in CD4+ T cell counts between these groups over the autumn 2009 through 
early winter 2010 observation period whether the vaccinated individuals with a change in 
HIV plasma virus load of > 1 log10 were included (−34, IQR −104-65) or excluded (−39, IQR 
−105-42) versus 10, IQR −21-28, (figure 1a). The small size of the group declining the 
vaccine (n = 12) precluded robust comparison of changes in CD4+ T cell numbers in 
inherently variable HIV-infected populations. Therefore, we also compared median change in 
circulating CD4+ T cell numbers within the vaccinated group over the period 1–5 months 
from receiving the vaccine to median change in CD4+ T cell numbers over an equivalent time 
period approximately 1 year later. While the seasonal flu vaccine in 2010 included 
A/California/07/09 H1N1, the ASO3 adjuvant was not used. Over the same time interval one 
year post A/California/07/09 H1N1 vaccination (2010/2011), the mean CD4+ T cell count of 
the H1N1-vaccinated group was 549 ± 283/μL initially and 573 ± 278/μL at the end of the 
observation period. There was no significant change in CD4+ T cell counts across this period 
(p = 0.3144, Mann–Whitney test). Excluding 4 cases where viral load rose or fell by > 1 log10 
over the observation period, the mean CD4+ T cell count of the H1N1-vaccinated group was 
stable at 584 ± 259/μL initially and 593 ± 259/μL at the end of the observation period. The 
median change in CD4+ T cell numbers over a 1–5 month interval spanning fall/winter 
2010/2011 was significantly different from the median change in CD4+ T cell counts that 
occurred in the 1–5 month (2009/2010) immediate post A/California/07/09 H1N1 vaccination 
period. This was consistent whether the 12 cases in 2009/2010 and 4 cases in 2010/2011 
where viral load rose or fell by > 1 log10 were included (−34, IQR −104-65 versus 15, IQR 
−56-92, p = 0.0128, Mann–Whitney test, figure 1b) or excluded from analysis (−39, IQR 
−105-42 versus 7.0, IQR −57-92, p = 0.0098, Mann–Whitney test, figure 1c). These data 
suggest that primary A/California/07/09 H1N1 ArepanrixTM vaccination had a slight and 
transient negative effect on circulating CD4+ T lymphocyte numbers in the group of HIV-
infected individuals studied. However, the effect was relatively minor compared to the 
overall variation in CD4+ T cell counts observed over the follow-up period. Therefore, after 
measuring vaccine responses, we carried out a sub-analysis within the vaccinated group 
comparing the median change in CD4+ T cell numbers of responders to the median change in 
CD4+ T cell numbers of non-responders over the period 1–5 months from receiving the 
vaccine. 
Table 1 General characteristics of H1N1 vaccine recipients and controls 
 Unvaccinated 
(n = 12) 
Vaccinated 
(n = 81) 
Responders 
(n = 36) 
Non-responders 
(n = 44) 
aCD4+ T cells/μL 
Mean ± SD 
420 ± 235 529 ± 269 609 ± 277 475 ± 241 
0–200 1 (8.3%) 9 (11%) 3 (8.3%) 5 (11%) 
201–350 5 (42%) 13 (16%) 4 (11%) 9 (20%) 
351–500 2 (17%) 15 (19%) 4 (11%) 11 (25%) 
>500 4 (33%) 44 (54%) 25 (69%) 19 (43%) 
Log10 viral load 
Median (IQR) 
1.60 (1.60-2.09) 1.60 (1.60-2.70) 1.60 (1.60-2.34) 1.60 (1.60-3.07) 
≤1.60 8 (67%) 50 (62%) 23 (64%) 27 (61%) 
1.61-2.60 3 (25%) 11 (14%) 7 (19%) 4 (9.1%) 
2.61-3.00 0 2 (2.5%) 1 (2.8%) 1 (2.3%) 
3.01-4.00 0 6 (7.4%) 1 (2.8%) 5 (11%) 
>4.00 1 (8.3%) 12 (14%) 4 (11%) 7 (16%) 
Age (years) 
Mean ± SD 
45.7 ± 6.6 45.2 ± 7.2 44.2 ± 7.5 46.2 ± 7.0 
Male 8 (67%) 56 (69%) 27 (75%) 29 (66%) 
Female 4 (33%) 25 (31%) 9 (25%) 16 (36%) 
bPre-existing anti-
H1N1 
ND 28 (35%) 22 (61%) 6 (14%) 
aNumber of CD4+ T cells/μL peripheral blood at time nearest to, but before H1N1 vaccination 
bNumber of individuals in each group with antibodies against H1N1 HA before vaccination 
Figure 1 Changes in CD4+ T lymphocyte counts in vaccine recipients and non-
recipients. Differences in CD4+ T cell counts between the nearest sampling time point before 
vaccination and a second time point within 1–5 months after vaccination are shown for the 
vaccine recipients. The groups labeled “Vaccinated I” include all individuals receiving the 
vaccine while those labeled “Vaccinated II” exclude individuals whose HIV virus load 
changed by > 1 log10 over the observation period. Changes in CD4
+ T lymphocyte counts over 
an equivalent period are shown for the group of non-vaccinated individuals (a). Changes in 
CD4+ T cells for the same group (I) and subgroup (II) of vaccine recipients over a similar 
time interval approximately 1 year later are compared in panels b and c to changes in CD4+ T 
cells observed over the post H1N1 vaccine period. Lines within groups show the group 
median with IQR and the p value indicating probability of no significant difference between 
groups is shown above lines spanning the groups being compared 
Vaccine responses 
In cases where pre-existing antibodies reactive with A/California/07/09 H1N1 HA antigen 
were present [baseline mean fluorescence intensity (MFI) ≥ 125], an increase of ≥ 250 MFI 
units was considered a positive response. For those individuals without pre-existing antibody 
responses against A/California/07/09 H1N1 HA, an increase in MFI to ≥ 250 was considered 
a positive vaccine response. Consistent results were obtained with repeat testing of 80 pre- 
and post-vaccination sample pairs. Applying the criteria stated above, 28/80 individuals had 
pre-existing antibodies reactive with A/California/07/09 H1N1 HA antigen, 36/80 (45%, 95% 
CI 34%-56%) HIV-infected individuals responded to the vaccine and 44/80 were non-
responders (figure 2a). Twenty-two of the 28 (79%, 95% CI 63%-94%) HIV-infected 
individuals with pre-existing antibodies against A/California/07/09 H1N1 HA antigen 
responded to the vaccine compared to only 14 of the 52 (27%, 95% CI 15%-39%) without 
pre-existing antibodies against A/California/07/09 H1N1 HA antigen. Thus, HIV-infected 
individuals with pre-existing antibodies against A/California/07/09 H1N1 HA antigen were 
considerably more likely to respond to the vaccine (p = 0.00001, Fisher’s exact test). If some 
of those individuals with pre-existing antibodies were actually infected with 
A/California/07/09 H1N1 HA antigen over the follow-up period for plasma collection, this 
could result in overestimation of the response rate in this group. A limitation in the 
retrospective design of our study was the variable timing in collection of post-vaccination 
plasma samples for analysis of anti- A/California/07/09 H1N1 HA antibody responses. 
Figure 2 Anti-H1N1 antibody levels detected by microbead-based array assay before 
and within 1–5 months after receiving the ASO3-adjuvanted A/California/07/09 H1N1 
influenza HA vaccine for 80 HIV-infected individuals (a). The dotted line at MFI 125 
separates individuals with pre-existing anti-H1N1 antibodies from those without. Comparison 
of the age distribution for vaccinated individuals categorized as non-responders, responders 
or responders with pre-existing antibodies against A/California/07/09 H1N1 HA (b). Lines 
within groups show the group median with IQR and the p value indicating probability of no 
significant difference between groups is shown above lines spanning the groups being 
compared 
Comparison of responders and non-responders 
There was no significant difference in mean age between responder and non-responder 
groups. However, as shown in figure 2b, responders without pre-existing antibodies against 
A/California/07/09 H1N1 HA antigen had a lower mean age (41.4 ± 5.7 years) than either 
responders with pre-existing antibodies (46.1 ± 8.0 years, p = .03, Student’s t test) or non-
responders (46.2 ± 7.0 years, p = .01, Student’s t test). Although there was a wide range of 
CD4+ T cell counts in both groups, the median CD4+ T cell count was significantly higher in 
the responder group than in the non-responder group (618, IQR 389–835 versus 446, IQR 
314–582, p = 0.0157, Mann–Whitney test, figure 3a). There was no significant difference in 
median CD4+ T cell nadir between responders and non-responders (126, IQR 83–199 versus 
143, IQR 61–202), nor between responders with or without pre-existing antibodies against 
A/California/07/09 H1N1 HA antigen (165, IQR 69–270 versus 210, IQR 63–314) 
respectively. Median plasma HIV viral load at the time of vaccination was not significantly 
different between groups and several responders had relatively high plasma levels of HIV 
(Figure 3b). The effect of multiple variables on vaccine response was assessed by stepwise 
logistic regression. Age, gender, time since immunization, pre- and post-immunization CD4+ 
T cell counts, pre- and post- HIV viral load, and CD4+ T cell nadir did not independently 
affect response to influenza vaccine. Pre-existing influenza antibody was the only predictor 
(F = 119.9; p=0.002) of vaccine response in both univariate and multivariate analyses. 
Figure 3 Comparison of (a) CD4+ T cell counts and (b) HIV viral loads between HIV-
infected responders and non-responders to the A/California/07/09 H1N1 vaccine. Lines 
within groups show the group median with IQR. The p value indicating probability of no 
significant difference between groups is shown above lines spanning the groups being 
compared 
Although the median loss of CD4+ T cells over the period 1–5 months from receiving the 
vaccine was significantly greater than over the same time period 1 year later, the effect was 
small relative to overall variation in CD4+ T cell counts. To test for specificity of the effect in 
relation to the effect of vaccination, we compared CD4+ T cell losses between HIV-infected 
vaccine recipients who exhibited an increase in anti-A/California/07/09 H1N1 antibodies and 
those who did not. Our reasoning was that if CD4+ T lymphocyte counts were affected by the 
vaccine, the impact would be greatest in those making a measurable immune response against 
it. There was a significantly greater median loss of CD4+ T cells over the period from 1–5 
months of receiving the A/California/07/09 H1N1 vaccine in the group of 36 individuals who 
responded to the vaccine compared to the 44 non-responders (−71, IQR −160-18 versus −31, 
IQR −80-78, p = 0.0214, Mann–Whitney test, figure 4a). Results were similar when 4 
responders and 8 non-responders whose HIV virus load changed by > 1 log10 over the 
observation period were excluded from analysis (−78, IQR −160-6.0 versus −36, IQR −80-
70, p = 0.0204, Mann–Whitney test, figure 4b). 
Figure 4 Changes in CD4+ T cell counts within 1 to 5 months of receiving the ASO3-
adjuvanted A/California/07/09 H1N1 influenza HA vaccine for HIV-infected responders 
and non-responders (a). In panel b, the changes in CD4+ T cell counts of individuals whose 
HIV virus load changed by > 1 log10 over the observation period were excluded from analysis. 
Lines within groups represent group median with IQR and the p value indicating probability 
of no significant difference between groups is shown above a line spanning the groups 
Discussion 
There was broad uptake of the pandemic A/California/07/09 H1N1 HA influenza vaccine in 
autumn 2009 in both high risk and general populations. Including the ASO3 adjuvant in the 
formulation increased immunogenicity of the vaccine in the general population with no 
indication of severe adverse events, but there are few studies on the performance of the 
vaccine formulation in HIV-infected individuals. Using a sensitive microbead-based array 
assay [13], we observed a low response rate overall in HIV-infected individuals (45%, 95% 
CI 34%-56%), especially in those with little or no evidence of pre-existing antibodies against 
A/California/07/09 H1N1 HA (27%, 95% CI 15%-39%). In contrast, the response rate was 
considerably higher in those subjects with pre-existing antibodies (79%, 95% CI 63%-94%). 
Responders had a higher mean CD4+ T cell count than non-responders and responders 
without pre-existing antibodies against A/California/07/09 H1N1 HA and were younger than 
the non-responders and responders with pre-existing antibodies against A/California/07/09 
H1N1 HA. Multivariate analysis did not indicate a difference in vaccine responsiveness, even 
when accounting for time since immunization. 
These data indicate a predictable hierarchy of vaccine effectiveness in which youth, lesser 
evidence of HIV disease progression and previous sensitization all favour responsiveness. 
Previous studies of this vaccine formulation in HIV-infected individuals reported response 
rates of > 65% using standard HA inhibition assays [9,14-16]. Although our assay format may 
be more sensitive [13] and identify a higher percentage of subjects with pre-existing 
antibodies, the response rate we observed overall was still considerably lower. The study 
cohorts with > 65% vaccine response rates were similar in terms of age, concurrent CD4+ T 
cell counts and extent of viral suppression below detectable levels. Most subjects in our 
cohort were infected 15 or more years ago and thus, may have had lower CD4+ T cell nadirs 
than subjects in the other groups. Another factor potentially contributing to the disparity in 
observed response rates is the different times after vaccination that vaccine responses were 
measured. A different, but comparable MF59-adjuvanted H1N1 HA vaccine induced similar 
antibody responses in HIV-infected and control study groups, but responses declined rapidly 
between 1 and 6 months post-vaccination in the HIV-infected group [17]. Another study with 
the MF59-adjuvanted vaccine reported seroconversion rates of only 36% in the HIV-infected 
study group, based on a minimum four-fold increase over baseline titer [18]. These other 
studies used standards related to vaccine protection to assess seroconversion, which require 
development of an HA inhibition titer of ≥ 1/40 or a fourfold increase over baseline titer. In 
contrast, we relied exclusively on a sizable increase in anti-H1N1 Ab levels to indicate an 
immune response to the vaccine and to categorize recipients as responders or non-responders. 
As the microbead-based assay measuring MFI is more sensitive to changes in anti-H1N1 
antibody levels than doubling dilution HA inhibition assays [13], this could influence a 
greater fraction of those with pre-existing anti-H1N1 Ab to be categorized as responders. If 
the response is subject to more rapid decay in non-sensitized HIV-infected individuals, then 
the longer time period we waited prior to assessment of responsiveness could have influenced 
a greater fraction overall to be categorized as non-responders. Obtaining samples 
systematically at earlier time points post vaccination could have changed our observed 
response rates. Overall, our results and others’ indicate that a prime-boost approach with this 
vaccine formulation might be more effective than a single administration at generating 
protective antibody levels in the HIV-infected population [19]. 
Another issue with use of this novel adjuvanted vaccine formulation in the HIV-infected 
population is the potential for adverse events associated with heightened or prolonged 
inflammation. While adverse events reported were primarily limited to localized pain, general 
fatigue and headache [1,3,8,9], we were struck by what appeared to be unusual declines in the 
CD4+ T cell counts of HIV-infected individuals within 1 to 5 months of receiving the 
vaccine. Therefore, we compared changes in CD4+ T cell counts between vaccine recipients 
and non-recipients, between vaccine responders and non-responders and among vaccine 
recipients over the post vaccine period and a similar time interval 1 year later. While the 
number of vaccine non-recipients in our study group was too low for robust comparisons, we 
did observe a slight, but significant fall in the CD4+ T cell numbers of vaccine recipients over 
the period following vaccination (November, 2009-March, 2010) compared to over a similar 
time period 1 year later. The fall in CD4+ T cell numbers over the time period following 
vaccination was significantly greater in the group of 36 vaccine responders compared to the 
group of 44 non-responders. In 2010, the seasonal flu vaccine did include 
A/California/07/2009 H1N1 HA, but was non-adjuvanted, suggesting the fall in CD4+ T cells 
observed post A/California/07/2009 H1N1 HA vaccination might reflect increased 
inflammation due to the adjuvant. If so, it may be informative to monitor CD4+ T cell counts 
at earlier time points post vaccination as it is somewhat surprising the effect persisted over 
the 1–5 months between pre and post-vaccination CD4+ T cell measurements. Again, our 
study was limited by its retrospective nature in that CD4+ T cell counts were not collected at 
completely systematic intervals relative to the timing of vaccination. Differences in CD4+ T 
cell changes over the 2009/2010 interval compared to 2010/2011 could also relate to the 
effects of primary versus booster vaccination with the inactivated A/California/07/2009 
H1N1 HA antigen itself. A stronger effect might actually be anticipated upon secondary 
exposure, but with more rapid resolution. The effect on CD4+ T cells was slight relative to 
overall variation in CD4+ T cell numbers over the study period, raising some question as to its 
direct relationship to vaccination and biological significance. Given the potential impact of 
infection with influenza, the minor and transient effect on CD4+ T cell numbers from the 
vaccine itself should probably not be a consideration for HIV-infected individuals [20]. With 
the timing of plasma collection post vaccination, we cannot exclude the possibility that 
several individuals categorized as vaccine responders actually developed anti-
A/California/07/2009 H1N1 antibodies as a result of infection. However, we feel it is more 
likely the observed accentuation of the effect in responders reflects the action of vaccine 
components affecting immunogenicity and reaffirms the general notion that immune 
activation can contribute to viral replication and the pathogenesis of CD4+ T cell loss in HIV 
infection [11,12,21]. Definition of operative mechanisms linking inflammation to CD4+ T 
cell loss in this light may be more relevant to the general pathogenesis of HIV infection than 
to vaccine-related adverse events. 
Conclusions 
The response rate to the pandemic 2009 ASO3-adjuvanted A/California/07/2009 H1N1 
vaccine ArepanrixTM was 45%, 95% CI 34%-56% overall in a group of HIV-infected 
individuals followed in Newfoundland and Labrador and only 27%, 95% CI 15%-39% in 
those without pre-existing anti-H1N1 antibody responses. Either a series of injections, 
reformulation or an increase in antigen content may be necessary to achieve desired response 
levels in this population [19,22]. Vaccine administration was associated with a minor, 
transient loss of CD4+ T cells, which was greater in vaccine responders. The small magnitude 
and limited durability of the loss compared to overall variation in CD4+ T cell numbers and in 
relation to risks associated with influenza infection itself, suggest it should not be an issue in 
recommending vaccination against influenza in the HIV-infected population, even with 
adjuvanted vaccine formulations. However, the CD4+ T cell loss could be an important 
illustration of the role immune activation plays in the pathogenesis of HIV infection. As such, 
confirmation of the effect and research towards understanding the underlying mechanism(s) 
are desirable. 
Methods 
Subjects 
This was a single centre retrospective study carried out in the provincial HIV clinic located in 
St. John’s, NL, Canada between October, 2009 and March, 2011. Ethical approval was 
received from the Health Research Ethics Authority of Newfoundland and Labrador. 
Individuals attending the St. John’s HIV clinic in autumn 2009 received priority access to the 
A/California/07/09 H1N1 vaccine ArepanrixTM (GlaxoSmithKline). The clinic nurse directly 
administered the vaccine to 81 HIV-infected individuals attending the clinic during the first 
week of October 2009 (vaccinated group), while 12 other HIV-infected individuals under the 
clinic’s care declined vaccination; these individuals comprise the unvaccinated group. Plasma 
samples were collected with informed consent as part of an ongoing research study on 
immune responses in HIV infection. Pre-and post-vaccination plasma samples were obtained 
from 80/81 vaccinated individuals. Lymphocyte subset counts and plasma virus load (Roche 
Amplicor®) measurements for time points immediately prior to (“pre-vaccine period”) and 
between 1 and 5 months post vaccination (“post-vaccine period”) were collected from clinical 
chart information. Measurements were taken from corresponding time periods for the 
unvaccinated group for comparison purposes. Changes in CD4+ T cell counts from the pre-
vaccine to post-vaccine period plasma samples were compared between the vaccinated and 
unvaccinated groups. In 12 cases where the plasma HIV viral load either rose or fell by more 
than 1 log10 across the pre and post vaccination span (4 responders and 8 non-responders), the 
changes in CD4+ T cell counts were excluded from comparison in sub-analyses, which were 
carried out separately. This was done because of the impact that large changes in HIV 
replication levels due to either de novo failure of, or response to antiretroviral therapy over 
the vaccine administration and follow-up period would likely have on CD4+ T cell numbers, 
irrespective of any vaccine effect. Comparison to changes in CD4+ T cell counts over a 
similar time period 1 year later was carried out within the vaccinated group using the same 1 
log10 change in plasma HIV viral load exclusion criteria for sub-analysis. 
Anti-A/California/07/09 H1N1 hemaglutinin HA antibody measurements 
Plasma samples from the pre-vaccine period and post-vaccine period were collected and 
stored at −80°C until tested. Antibody levels against the A/California/07/09 H1N1 HA 
antigen and 11 additional influenza HA antigens before and after vaccination were measured 
as in [13]. Briefly, recombinant HA antigens were coupled to 5.5 μm microspheres, which 
were then incubated with plasma samples. Antibodies binding to the beads were subsequently 
detected with biotinylated anti-human IgG antibodies and fluorochrome-conjugated avidin. 
The intensity of the anti-human IgG bound fluorochrome is proportional to the amount of 
antibody bound to A/California/07/09 HA, which is calculated by flow cytometry with 
calibrated standards. Where antibodies reactive with A/California/07/09 H1N1 HA antigen 
were present at baseline (MFI ≥ 125), increases of ≥ 250 MFI units were considered to 
indicate positive humoral responses to the vaccine. Without pre-existing antibody responses 
against A/California/07/09 H1N1 HA, increases in MFI to ≥ 250 were considered to indicate 
positive humoral responses to the vaccine. 
Statistical analysis 
Data sets were assessed for normal distribution by the Kolmogorov-Smirnov, D’Agostini and 
Pearson and Shapiro-Wilk tests. If all three tests indicated a normal distribution, data was 
represented with mean ± standard deviation (SD) shown for the different groups and 
Student’s t test was used to compare means. If any of the data sets being compared did not 
meet test criteria for normal distribution, groups were compared by Mann–Whitney test. A 
one-tailed probability of less than 0.05 was considered significant. The difference in 
distribution of vaccine responses between groups with or without pre-existing anti-H1N1 
antibodies was compared by Fisher’s exact test. Stepwise multiple logistic regression was 
performed using SPSS 19.0 statistical software to control for confounding variables. 
List of abbreviations: Ab, Antibody; HA, Hemaglutinin; HAART, Highly active 
antiretroviral therapy; HIV, Human immunodeficiency virus; IgG, Immunoglobulin G; IQR, 
Interquartile range; MFI, Mean fluorescence intensity; SD, Standard deviation; μg, 
Microgram; μL, Microliter 
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